We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IMI:LSEIMI plc Analysis

Data as of 2026-03-14 - not real-time

£2,640.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

IMI plc is trading at £2,640, comfortably above its 20‑day SMA of 2,815.9 and 50‑day SMA of 2,759.2, yet still below the 200‑day SMA of 2,399.2, indicating a short‑term pull‑back within a longer‑term bullish framework. The RSI of 36.6 and a bearish MACD histogram of –23.2 suggest the stock is nearing oversold conditions, while the increasing volume and a clear support level at £2,626 reinforce a potential bounce. Valuation metrics are mixed: a forward PE of 17.4 and a current PE of 21.3 are well under the industry average of 29.1, implying relative value, but the DCF‑derived fair value of £1,689.6 marks the market price as significantly overvalued, limiting upside to roughly 13%. Fundamentally, IMI delivers solid growth with 9.1% revenue expansion, a 28% ROE, and healthy margins (gross 47%, operating 22%). The dividend yield of 1.24% is supported by a modest payout ratio of 26% and strong free cash flow, indicating sustainability. Recent strategic moves, such as the sale of Truflo Marine, and routine dividend record‑date adjustments signal active capital management, while the company’s global footprint diversifies geographic risk.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI near oversold territory
  • Support level at £2,626
  • Bearish MACD signal

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Revenue growth of 9.1% and strong ROE
  • Undervalued relative to industry PE
  • Upside potential of ~13% from current price

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Sustainable dividend with low payout ratio
  • Diversified global operations reducing geographic risk
  • Strategic portfolio adjustments (e.g., Truflo Marine sale) supporting long‑term resilience

Key Metrics & Analysis

Financial Health

Revenue Growth9.10%
Profit Margin13.45%
P/E Ratio21.3
ROE28.25%
ROA10.57%
Debt/Equity58.04
P/B Ratio585.4
Op. Cash Flow£415.3M
Free Cash Flow£234.4M
Industry P/E29.1

Technical Analysis

TrendBullish
RSI36.6
Support£2,626.00
Resistance£2,926.00
MA 20£2,815.90
MA 50£2,759.20
MA 200£2,399.20
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair Value£1,689.58
Target Price£2,990.67
Upside/Downside13.28%
GradeFair
TypeBlend
Dividend Yield1.24%

Risk Assessment

Beta0.50
Volatility26.86%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.